Replies to post #12 on Alseres Pharmaceuticals, Inc. (ALSE)

[funnyG986]

ALSE approaching end of phase III clinic trial. bidding some more 0.035, lotto ticket.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/

[funnyG986]

ALSE vol. chart seems someone preload 700k back in June. Phase III clinic trial.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/